Direct Indexing in New Jersey: 32.77%–34.55% Combined LTCG Rate

New Jersey provides no preferential tax rate for long-term capital gains — the state taxes all capital gains as ordinary income at the same marginal rates as wages and interest. For a pharma executive, finance professional, or business owner with income above $500,000, the combined federal and New Jersey rate on long-term capital gains runs from 32.77% to 34.55%. That's 37%–45% more than in Texas or Florida, and modestly lower than New York City only because NJ has no city income tax. In 2026, New Jersey also enacted QSBS conformity for the first time, creating meaningful planning opportunities for pharma and biotech founders. Here's what that means for your direct indexing math.

Why New Jersey investors face high combined LTCG rates

At the federal level, long-term capital gains are taxed at 0%, 15%, or 20% depending on income — a preferential rate relative to ordinary income. New Jersey provides no equivalent preference. New Jersey Gross Income Tax applies to capital gains at the same marginal rates as ordinary income — 1.4% to 10.75% — with no distinction between short-term and long-term holding periods.¹

The 2026 New Jersey Gross Income Tax rate schedule:

For direct indexing clients — typically high-income professionals with significant taxable accounts — the combined LTCG rate stacks federal and state as follows:

The 20% federal LTCG rate applies to income above approximately $545,500 (single) or $613,700 (MFJ) in 2026 per IRS Rev. Proc. 2025-32. Federal NIIT of 3.8% applies above $200,000 (single) or $250,000 (MFJ). NJ does not have a separate NIIT-equivalent tax.

Break-even table: NJ vs. NYC vs. TX/FL

The following table shows estimated annual net benefit of direct indexing at a 1.5% annual harvest rate against a fee premium of 0.25%/year. The NJ top column uses 34.55% (income above $1M); the NJ mid column uses 32.77% (income $500K–$1M). NYC uses 37.3% (9.65% NY state + 3.876% city + 23.8% federal, income $1M–$5M range).

Assumes 1.5%/year harvest rate (approximation — actual rates vary significantly with market conditions), 0.25% DI fee premium over a low-cost ETF alternative. NJ top uses 34.55% combined (10.75% NJ + 20% federal LTCG + 3.8% NIIT). NJ mid uses 32.77% (8.97% NJ). NYC uses 37.3% (9.65% NY state + 3.876% NYC city + 23.8% federal). TX/FL uses 23.8% federal only. These are estimates, not guarantees.

Who reaches the top combined rate in New Jersey

The 10.75% NJ rate applies to New Jersey income above $1,000,000. Most direct indexing clients in New Jersey who reach this level include:

• Pharmaceutical and biotech executives at major NJ employers — Merck (Rahway), Johnson & Johnson (Raritan Valley campus), Bristol-Myers Squibb (Princeton Pike), Novo Nordisk (Plainsboro), Sanofi (Bridgewater), Daiichi Sankyo (Basking Ridge), Bayer (Whippany) — with substantial RSU vesting, NQSO income, or ESPP proceeds that push total income above $1M in vesting-heavy years
• Finance professionals in NJ suburbs (Hoboken, Jersey City, Summit, Short Hills, Morristown) who work at Wall Street firms — investment bankers, traders, hedge fund and PE managers — with six- and seven-figure annual income and accumulated taxable portfolios
• Business owners and founders who sold a NJ-based company and reinvested exit proceeds into a taxable account
• Real estate investors with large §1231 gain events from NJ property sales
• Attorneys at NJ or NYC law firms with substantial equity partnership distributions

Investors with income between $500,001 and $1,000,000 face a 32.77% combined rate — still substantially above the federal-only 23.8% baseline. The break-even math for a $1M taxable account remains solidly positive at this bracket (+$2,416/year net of fees).

New Jersey QSBS conformity — effective January 1, 2026

The most significant New Jersey tax development of 2025 for direct indexing clients: New Jersey enacted QSBS conformity for the first time. Governor Phil Murphy signed Bill A4455/S4503 on June 30, 2025, bringing NJ into alignment with IRC §1202 for tax years beginning on or after January 1, 2026.³⁴

Prior to 2026, New Jersey was one of only five states — along with California, Alabama, Mississippi, and Pennsylvania — that did not conform to the federal qualified small business stock exclusion. NJ residents who sold QSBS and excluded the gain federally still owed full NJ Gross Income Tax at up to 10.75% on the entire gain.

Starting in 2026:

• Gains excluded under §1202 for federal purposes are also excluded from New Jersey GIT — even if the shares were issued before 2026
• For QSBS acquired after July 4, 2025, investors may benefit from the enhanced OBBBA rules: 50% exclusion at 3-year hold, 75% at 4 years, 100% at 5 years, with a $15M per-issuer cap³
• The NJ QSBS payroll-location test (requiring the company to have been a NJ "qualified business") applies to the NJ exclusion specifically — verify with a tax attorney for your company's facts

Timing consideration: The NJ conformity is prospective — effective for tax years beginning January 1, 2026. Founders who sold QSBS in 2025 did not benefit from the new NJ exclusion. For founders considering a 2026 liquidity event or earnout structure, the NJ timing now matters as much as the federal holding-period analysis.

The interplay with direct indexing: even if your QSBS gains are excluded at both federal and NJ levels, you may have non-QSBS gain events in the same year (earnout payments, rollover equity dispositions, salary, K-1 income). A DI loss bank still provides value by offsetting those other capital gains at the 34.55% combined rate.

NJ pharma corridor: RSU and NQSO holders

New Jersey is the center of U.S. pharmaceutical and life sciences employment. Merck, J&J, BMS, Novo Nordisk, Sanofi, Daiichi Sankyo, Bayer, and dozens of mid-sized pharma and biotech companies maintain major NJ operations. Pharma employees at these companies typically have:

• Annual RSU vesting: ordinary income at vesting, taxed at combined 37% federal + 8.97%/10.75% NJ + payroll taxes on the spread
• NQSO exercises: same ordinary-income treatment on the exercise spread (see NQSO guide)
• ESPP sales: ordinary income on the discount, potential LTCG on the excess appreciation
• Accumulated appreciated shares from prior vesting cycles: long-term capital gains when sold, taxable at 32.77%–34.55% combined in NJ

How direct indexing fits for NJ pharma employees:

• Fund the DI account with fresh-vest proceeds: Newly vested shares (or their cash equivalent) have a cost basis equal to the vesting-day price — no embedded gain. Contributing these to a DI account starts building a loss bank without triggering a taxable event.
• Use the DI loss bank to fund sales of older tranches: RSU shares from 2020–2022 vests that have appreciated significantly carry embedded gains. Each $10,000 of harvested DI losses offsets $10,000 of gain from selling older tranches at the 32.77%–34.55% combined NJ rate.
• Configure the employer-stock exclusion screen: A DI portfolio must exclude your employer's stock from its individual-stock holdings. Otherwise, harvested losses on (for example) MRK shares in your DI portfolio are wash-sales if you're receiving new MRK shares through payroll RSU vesting within 30 days. A specialist advisor configures this screen at setup.

Finance commuters living in New Jersey

Many finance professionals at major banks, asset managers, hedge funds, and private equity firms choose to live in New Jersey (Hoboken, Jersey City, Summit, Short Hills, Morristown, Princeton area) while working in Manhattan. The capital gains tax mechanics for this group:

Capital gains are sourced to domicile. A NJ-domiciled investor's capital gains from a taxable brokerage account are subject to NJ tax — not NYC city tax. New Jersey residents who commute to Manhattan do not pay New York City resident income tax on investment income. NYC's 3.876% city tax applies only to legal residents of New York City's five boroughs.

Wages are different from capital gains. NJ residents who earn wages while physically working in New York City owe New York State income tax on those wages. NJ provides a credit for the NY state tax paid on the NJ return. For capital gains, however, NJ residents pay NJ tax only — not NY state, not NYC city.

The NJ rate is higher than many NY state rates, but lower than NYC total. A NJ resident with $1M+ income pays 10.75% NJ state on capital gains. The equivalent NYC resident pays 9.65% NY state + 3.876% NYC city = 13.526% combined state+local. The NJ commuter saves the city tax, but pays a modestly higher state rate than an equivalent NY state resident outside NYC.

NJ estate and inheritance tax context

New Jersey eliminated its estate tax in 2018 — NJ no longer imposes a separate estate tax at death. However, New Jersey retains an inheritance tax on transfers to non-immediate-family beneficiaries (Class C and D transferees). For direct indexing planning, the two relevant points:

• The §1014 step-up still applies at the federal level. Appreciated DI lots that pass to heirs at death receive a step-up in cost basis to fair market value, eliminating the embedded capital gain for the heir. NJ does not impose a separate capital gains tax at death — heirs who later sell inherited DI shares pay NJ tax only on appreciation occurring after the step-up date. This preserves the same §1014 planning opportunity as in other states.
• NJ inheritance tax is on the transfer, not the gains. The NJ inheritance tax (0%–16% depending on beneficiary class) is assessed on the value of assets transferred, not on the capital gains embedded in them. This is separate from and not affected by the step-up mechanism.

Platform selection for New Jersey investors

All major direct indexing platforms serve NJ investors through advisor networks. Considerations specific to NJ and the tristate commuter community:

• Parametric and Aperio (advisor-only, $250K–$1M+ minimums) are the strongest choices for NJ finance professionals with PE carry, K-1 multi-character events, or multi-account wash-sale exposure across multiple custodians. For NJ pharma executives with RSU, NQSO, and ESPP in multiple accounts, advisor-coordinated platforms are the only way to ensure cross-account wash-sale compliance.
• Vanguard Personalized Indexing (~$250K minimum, 0.20% fee) and IBKR Custom Indexing (no formal minimum, commission-based) offer cost-efficient options for cost-sensitive advisors and clients who want to minimize platform fees while still accessing DI-level harvesting.
• Schwab Personalized Indexing and Wealthfront ($100K minimum) are accessible entry points for NJ investors who don't have PE carry or K-1 complexity. Their wash-sale monitoring is limited to their own platforms — creating risk if you also hold employer stock in a 401(k) or multi-account setup typical of pharma and finance professionals.
• NJ QSBS planning note: Founders who just had a qualifying liquidity event (and excluded the gain) may still want a DI account for the reinvested proceeds. Even with QSBS proceeds excluded at both federal and NJ levels, future capital appreciation on reinvested assets will be subject to 32.77%–34.55% combined NJ rates — making early DI deployment valuable for the next growth cycle.

Sources

1. New Jersey Division of Taxation — NJ Income Tax Rates and Tax Tables. NJ Gross Income Tax applies to capital gains at the same marginal rates as ordinary income: 1.4% through 10.75%. No preferential rate exists for long-term gains under New Jersey law. 2026 brackets confirmed per NJ Division of Taxation guidance; brackets are fixed in statute and not inflation-adjusted.
2. NJBIA — NJ Individual State Income Tax Rate Remains 4th Highest in Nation for 2026. New Jersey's top marginal rate of 10.75% (income above $1M) is confirmed as the 4th highest individual income tax rate in the United States for 2026.
3. EisnerAmper — New Jersey to Allow Exclusion of Qualified Small Business Stock Gains (2025). New Jersey enacted QSBS conformity effective January 1, 2026 via Bill A4455/S4503 (signed June 30, 2025). Gains excluded under IRC §1202 for federal purposes are now also excluded from NJ Gross Income Tax. Prior to 2026, NJ did not conform to §1202.
4. Mintz — New Jersey Adopts QSBS Exclusion: A Game-Changer for In-State Investors and Founders (July 2025). Analysis of NJ Bill A4455/S4503 — scope of exclusion, effective date, OBBBA interaction, and application to pre-2026-issued QSBS. Effective for tax years beginning on or after January 1, 2026.
5. Tax Foundation — State Capital Gains Tax Rates, 2026. NJ top LTCG rate: 10.75% (income above $1M), applied as ordinary income. CA: 13.3%. NY: 10.9% top (above $25M). CT: 6.99%. TX and FL: 0%. Federal LTCG + NIIT at top bracket: 23.8%.
6. IRS Rev. Proc. 2025-32 — 2026 Federal Tax Thresholds. 2026 federal LTCG rate thresholds: 20% rate begins at $545,500 (single) / $613,700 (MFJ). NIIT threshold: $200,000 (single) / $250,000 (MFJ), not inflation-adjusted per IRC §1411.

New Jersey income tax rates verified against NJ Division of Taxation and NJBIA guidance as of May 2026. NJ QSBS conformity verified per EisnerAmper, Mintz, and NJ legislation tracking (Bill A4455/S4503, signed June 30, 2025). Federal LTCG thresholds verified per IRS Rev. Proc. 2025-32. Harvest rate estimates (1.5%/year) are based on industry research and may vary significantly with market conditions. This page is informational only and does not constitute financial, tax, or legal advice. Consult a CPA or tax attorney for your specific situation.